WHW. N. Huang

W. N. Huang

*This is an algorithmically generated author record based on publicly available information.

W. N. Huang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • C. T. Lin

    Taichung Veterans General Hospital, Division of allergy, Immunology and Rheumatology, Department of internal Medicine, Taichung, Taiwan, Republic of China

    2 shared publications
  • Y. H. Chen

    Taichung Veterans General Hospital, Division of allergy, Immunology and Rheumatology, Department of internal Medicine, Taichung, Taiwan, Republic of China

    2 shared publications
  • Y. M. Chen

    Taichung Veterans General Hospital, Division of allergy, Immunology and Rheumatology, Department of internal Medicine, Taichung, Taiwan, Republic of China

    2 shared publications
  • C. H. Lin

    Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China

    1 shared publication
  • Francis K. L. Chan

    Microbiota I-Center (MagIC)

    1 shared publication
  • H. H. Chen

    Taichung Veterans General Hospital, Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Roseburia hominis improves host metabolism in diet-induced obesity

    by Wenli Huang, Wenyi Zhu, Yu Lin, Francis K. L. Chan, Zhilu Xu, Siew C. Ng

    Next-generation live biotherapeutics are promising to aid the treatment of obesity and metabolic diseases. Here, we reported a novel anti-obesity probiotic candidate, Roseburia hominis, that was depleted in stool samples of obese subjects compared with lean controls, and its abundance was negatively correlated with body mass index and serum triglycerides. Supplementation of R. hominis prevented body weight gain and disorders of glucose and lipid metabolism, prevented fatty liver, inhibited white adipose tissue expansion and brown adipose tissue whitening in mice fed with high-fat diet, and boosted the abundance of lean-related species. The effects of R. hominis could be partially attributed to the production of nicotinamide riboside and upregulation of the Sirtuin1/mTOR signaling pathway. These results indicated that R. hominis is a promising candidate for the development of next-generation live biotherapeutics for the prevention of obesity and metabolic diseases.


  • Open Access

    POS0279 THE ABCG2 rs2231142 POLYMORPHISM ARE ASSOCIATED WITH RISK OF NEPHROLITHIASIS IN A TAIWANESE POPULATION.

    by C. T. Lin, Y. H. Chen, I. C. Chen, W. N. Huang, C. H. Lin, Y. M. Chen

    Background In genome-wide association studies (GWAS), the strong association of ABCG2 rs2231142 variant with hyperuricemia and gout was confirmed in Asian population. Additionally, the obesity, diet, lifestyle, genetics and underlying comorbidities are important risks factors predisposing to hyperuricemia and gout. The systematic reviews revealed a significant link between obesity, systemic comorbidities and hyperuricosuria for predisposition of kidney stones (nephrolithiasis). However, whether ABCG2 plays an important role in the phathogenesis of nephrolithiasis remain unclear. The interaction between genetic factors and other risk factors of nephrolithiasis is still elusive. Objectives In this study, we want to explore the association between ABCG2 rs2231142 variant and the risk of nephrolithiasis in modern Taiwanese population, and clarify the role of uric acid in nephrolithiasis formation. Methods This retrospective case-control study was conducted using the Taiwan Biobank database. A total of 120,267 individuals of Taiwanese Han Chinese aged 30-70 years were enrolled in the study. The primary outcome was the incidence of self-reported nephrolithiasis. Odds ratio (OR) of incident nephrolithiasis was analyzed by multiple logistic regression models and the interaction between ABCG2 rs2231142 variants, serum uric acid level, on the nephrolithiasis was explored. The multifactorial confounding factors for prediction of nephrolithiasis were also re-examined in our study. Results Finally, we identified 8,410 participants with nephrolithiasis and the prevalence was 11.52% and 4.37% in men and women, respectively. Older age (OR=1.08, 95% CI: 1.02-1.03, ppppppp=0.002), and hyperuricemia (OR=1.06, 95% CI: 1.04-1.08, pppp=0.083). Participants with regular physical exercise is a protective factor from nephrolithiasis (OR=0.95, 95% CI:0.9-1.0, p=0.048). Conclusion Our study demonstrated the risk of nephrolithiasis is significant association with ABCG2 rs2231142 variants. This risk also increased with systemic comorbidities (hyperlipidemia, hypertension, diabetes mellitus, and hyperuricemia), and lifestyle (obesity, and smoking). Regular physical exercise is associated with protective factor for incident nephrolithiasis. Adjusted Odds ratio of kidney stone. Disclosure of Interests None declared

  • Open Access

    POS1249 EFFICACY AND SAFETY OF ChAdOx1 nCoV-19/AZD1222 AND mRNA-1273 VACCINES: A COMPARATIVE STUDY IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES

    by Yi‐Ju Chen, W. N. Huang, H. H. Chen, H. W. Chen, P. L. Cheng, J. P. Chen, C. T. Lin, K. T. Tang, W. T. Hung, T. Y. Hsieh, et al.

    Background Several studies have demonstrated immunogenicity after COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD) [1], but the differences between mRNA-based and vector vaccines and the cellular responses to COVID-19 vaccines according to distinct immunogenicity in AIRD patients are still unclear. Objectives To investigate the differences in efficacy and safety between the vector vaccine ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca) and mRNA-based vaccine mRNA-1273 (Moderna) in patients with AIRD, and to explore the cell-cell interactions between high and low anti-SARS-CoV-2 IgG levels in patients with rheumatic arthritis (RA) by single-cell RNA sequencing (scRNA-seq). Methods From September 16 to November 15, 2021, we consecutively enrolled 243 participants aged ≥20 years with AIRD who received COVID-19 vaccination, of whom 113 were immunized with AZD1222 and 130 with mRNA-1273. The level of serum IgG antibodies to the SARS-CoV-2 receptor-binding domain on the spike protein S1 subunit was quantified by electrochemiluminescence immunoassay at 4-6 weeks after vaccination. Moreover, peripheral blood mononuclear cells were isolated from two RA patient with high anti-SARS-CoV-2 IgG level and four RA patients with low level for scRNA-seq and cell-cell communication signal was analyzed by CellChat. Results The anti-SARS-CoV-2 IgG seropositivity rate was 78.8% (89/113) for AZD1222 and 83.1% (108/130) for mRNA-1273. The level of anti-SARS-CoV-2 IgG was higher in patients who received mRNA-1273 than in those who received AZD1222 (β: 30.15, 95% CI: 11.67-48.63, p=0.002) (Table 1). Prednisolone-equivalent dose >5 mg/day and methotrexate (MTX) use in AIRD patients, and non-anti-tumor necrosis factor (TNF)-α biologics and Janus kinase (JAK) inhibitor use in RA patients were associated with inferior immunogenicity. ScRNA-seq revealed CD16-monocytes were predominant in RA patients with high anti-SARS-CoV2-IgG antibody level, and enriched pathways related to antigen presentation via major histocompatibility complex class II (MHC class II) were found (Figure 1). HLA-DRA and CD4 interaction was vigorous among all identified MHC-II pathway and was enhanced in high anti-SARS-CoV2-IgG antibody group. Multivariate analysis of anti-SARS-CoV-2 IgG level in patients with rheumatic diseases following COVID-19 vaccines The comprehensive cell atlas of PBMC of RA patients with high and low anti-SARS-CoV2-IgG antibodies. A) UMAP visualization of PBMC cells from RA patients. B) The proportion of cell types between high and low antibody groups. C) Volcano plot of CD16-monocyte showed differential expressed genes. D) Pathway analysis between high and low antibody groups; PRBC: peripheral blood mononuclear cell, RA: rheumatoid arthritis, NK cell: natural killer cell, pDC: plasmacytoid dendritic cell, CLP: common lymphoid progenitor. Conclusion mRNA-1273 and AZD1222 vaccines exhibited differential immunogenicity in patients with AIRD. Enriched pathways related to antigen presentation via MHC class II in CD16-monocytes might be associated with higher anti-SARS-CoV2-IgG level in RA patients and further study is warranted. References [1]Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80:1306-1311. Acknowledgements The authors thank the Biostatistics Task Force of Taichung Veterans General Hospital for their assistance with the statistical analysis in this study. Disclosure of Interests None declared